Investment Analysts’ Recent Ratings Changes for GlycoMimetics (GLYC)

GlycoMimetics (NASDAQ: GLYC) has recently received a number of price target changes and ratings updates:

• 8/2/2024 – GlycoMimetics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/26/2024 – GlycoMimetics was downgraded by analysts at TD Cowen from a “buy” rating to a “hold” rating.
• 7/25/2024 – GlycoMimetics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/17/2024 – GlycoMimetics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/9/2024 – GlycoMimetics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 7/1/2024 – GlycoMimetics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 6/23/2024 – GlycoMimetics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 6/15/2024 – GlycoMimetics is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.

GlycoMimetics Trading Up 0.7 %

NASDAQ:GLYC traded up $0.00 during midday trading on Wednesday, hitting $0.18. 743,676 shares of the company traded hands, compared to its average volume of 2,217,792. The firm has a market capitalization of $11.64 million, a P/E ratio of -0.31 and a beta of 2.19. The firm’s fifty day moving average is $0.27 and its 200-day moving average is $1.57. GlycoMimetics, Inc. has a 12-month low of $0.17 and a 12-month high of $3.53.

GlycoMimetics (NASDAQ:GLYC) last posted its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). On average, research analysts expect that GlycoMimetics, Inc. will post -0.61 EPS for the current fiscal year.

Insider Transactions at GlycoMimetics

In other GlycoMimetics news, major shareholder Public Equities L.P. Invus sold 363,949 shares of GlycoMimetics stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $0.24, for a total transaction of $87,347.76. Following the completion of the transaction, the insider now owns 7,966,780 shares in the company, valued at approximately $1,912,027.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, major shareholder Public Equities L.P. Invus sold 363,949 shares of the firm’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $0.24, for a total transaction of $87,347.76. Following the sale, the insider now owns 7,966,780 shares of the company’s stock, valued at approximately $1,912,027.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Edwin Rock bought 190,000 shares of the business’s stock in a transaction dated Thursday, June 20th. The shares were purchased at an average cost of $0.25 per share, with a total value of $47,500.00. Following the completion of the acquisition, the insider now owns 565,403 shares in the company, valued at $141,350.75. The disclosure for this purchase can be found here. Insiders have sold 685,848 shares of company stock worth $163,332 over the last 90 days. 8.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On GlycoMimetics

Hedge funds have recently bought and sold shares of the business. Acadian Asset Management LLC grew its position in shares of GlycoMimetics by 61.8% in the second quarter. Acadian Asset Management LLC now owns 534,753 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 204,227 shares during the period. Advisor OS LLC purchased a new position in GlycoMimetics in the 4th quarter valued at about $238,000. Finally, Vanguard Group Inc. boosted its holdings in GlycoMimetics by 14.0% in the 1st quarter. Vanguard Group Inc. now owns 2,761,981 shares of the biotechnology company’s stock worth $8,286,000 after buying an additional 340,112 shares during the last quarter. Hedge funds and other institutional investors own 75.19% of the company’s stock.

GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.